Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
Completed
Sue Goldstein
Phase 4
2015-07-01
This is an unblinded study to be conducted at a single research center, San Diego Sexual
Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene
daily for twenty weeks. After the informed consent is signed, a baseline physical
examination, and vulvoscopy with detailed photography of the vulva, vestibule and vagina,
will be performed. Physical examination and vulvoscopy with detailed photography of the
vulva, vestibule and vagina, will be repeated prospectively every 4 weeks for a total of 20
weeks. Therefore, physical examination and vulvoscopy with detailed photography of the vulva,
vestibule and vagina will be performed prospectively at baseline (vulvoscopy session 1), 4
weeks (vulvoscopy session 2), 8 weeks (vulvoscopy session 3), 12, weeks (vulvoscopy session
4), 16 weeks (vulvoscopy session 5) and 20 weeks (vulvoscopy session 6) following daily
administration of 60 mg ospemifene.
Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
Terminated
Emory University
Phase 4
2017-06-30
Vulvovaginal atrophy (VVA) is a condition that impacts up to 60% of the growing
postmenopausal female population, and the most common symptom is dyspareunia. Vaginal
estrogen is the most common treatment for VVA, but it only marginally improves overall sexual
function, and many women and clinicians avoid using it because of the risks of exogenous
estrogen use during menopause. Ospemifene is a non-estrogen selective estrogen receptor
modulator (SERM) that is FDA-approved for treating dyspareunia related to VVA, and has shown
superb improvements in overall sexual health. 104 women will be randomized to receive 12
weeks of 60mg oral ospemifene, taken daily, or 12 weeks of 0.5mg vaginal conjugated
estrogens, which is placed vaginally twice per week. The improvements in sexual health and
VVA symptom severity will be compared in each group. This study will help determine if
ospemifene is a better treatment medication than conjugated estrogens.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
